Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Earnings should be great?

$Emergent BioSolutions(EBS.US)$ Heres a few highlights of why im so stoked to see YoY numbers! Look how they have       Strengthened Their Portfolio
•Launched NARCAN® Nasal Spray over-the-counter opioid overdose reversal treatment in the U.S., in addition to distributing over 20 million doses (10 million two-dose boxes) in the U.S. and Canada
•Secured a new $235.8 million contract with U.S. Dept. of Defense for BioThrax® (Anthrax Vaccine Adsorbed)
•Signed a new $379.6 million U.S. Dept. of Defense contract for RSDL® (Reactive Skin Decontamination Lotion Kit)
•Received U.S. FDA approval of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), formerly AV7909, a two-dose anthrax vaccine for post-exposure prophylaxis use
•Awarded a $75 million option to Emergent’s existing contract for the acquisition of anthrax vaccine CYFENDUS®
•Awarded a 10-year contract by BARDA for advanced development, manufacturing scale-up, and procurement of Ebanga™ (ansuvimab-zykl), a treatment for Ebola 1
•Submitted supplemental Biologics License Application to FDA for ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) vaccine for immunization against Mpox virus Improved Financial Position
•Implemented organizational changes resulting in $60 million in annual savings
•Shifted resource deployment resulting in $100 million in annual savings
•Amended and extended maturity of our secured credit facility to May 2025
•Travel Health business divestiture – valued at up to $380 million
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
5
1
+0
13
Translate
Report
12K Views
Comment
Sign in to post a comment

View more comments...

2499Followers
28Following
33KVisitors
Follow